We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial
Read MoreHide Full Article
Leading dialysis service provider DaVita Inc (DVA - Free Report) , through its subsidiary DaVita Clinical Research ("DCR"), recently announced the expansion of its research services to include Alliance Site Network. It is said to be a turnkey solution for pharmaceutical companies seeking dedicated research sites for patients with chronic kidney disease (CKD) and conditions directly related to it, but who are not yet on dialysis.
As per the press release, Alliance Site Network targets to bring clinical research infrastructure to nephrology partner practices around the U.S., creating research sites in those locations. Under DaVita’s subsidiary, the network will receive onsite operational support and dedicated clinical staff to perform each trial under the direction of an independent principle investigator.
Additionally, DCR will supervise all research aspects including start-up, trial oversight and quality management, among many other services, and will work directly with a contracted investigator within the nephrology partner practice.
Meanwhile, over the last one month, DaVita has been going through a rough phase. The share price has been trading below the Zacks categorized Medical - Outpatient and Home Healthcare industry. The company has gained 2.5%, compared to the 4% gain of the broader industry over the same period. We expect DaVita’s constant efforts to upgrade kidney-care services with initiatives like Alliance Site Network to boost the share price in the near term.
Coming back to the news, management claims that of late there has been a rise in demand for clinical trials within a unified network for patients with early stage kidney disease. DaVita’s operating and quality systems, combined with its network of independent nephrologists, meet that need.
The company, through DCR, has opened 10 Alliance Sites in seven states. Clinical trials at these sites will emphasize on the growing pipeline of new therapies for CKD stages 1 through 4 and other conditions manifesting as a result of kidney disease. The company also plans to open an additional five Alliance Sites by the end of 2017 with further expansion planned in 2018 and beyond.
Apart from this, DaVita operates Affiliate Site Network, a similar clinical research program through DCR. This network conducts clinical research trial for end stage renal disease patients receiving hemodialysis at around 200 DaVitadialysis centers across the U.S.
As per an Allied Market Research report, the global dialysis market is estimated to reach a worth of $118.5 million by 2023, registering a CAGR of 4.5% from 2017 to 2023. This provides ample scope for DaVita to cash in on opportunities in this growing market.
Zacks Rank & Key Picks
DaVita currently carries a Zacks Rank #3 (Hold). Some better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technology and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock added roughly 21% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 96%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 17% over the last three months.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial
Leading dialysis service provider DaVita Inc (DVA - Free Report) , through its subsidiary DaVita Clinical Research ("DCR"), recently announced the expansion of its research services to include Alliance Site Network. It is said to be a turnkey solution for pharmaceutical companies seeking dedicated research sites for patients with chronic kidney disease (CKD) and conditions directly related to it, but who are not yet on dialysis.
As per the press release, Alliance Site Network targets to bring clinical research infrastructure to nephrology partner practices around the U.S., creating research sites in those locations. Under DaVita’s subsidiary, the network will receive onsite operational support and dedicated clinical staff to perform each trial under the direction of an independent principle investigator.
Additionally, DCR will supervise all research aspects including start-up, trial oversight and quality management, among many other services, and will work directly with a contracted investigator within the nephrology partner practice.
Meanwhile, over the last one month, DaVita has been going through a rough phase. The share price has been trading below the Zacks categorized Medical - Outpatient and Home Healthcare industry. The company has gained 2.5%, compared to the 4% gain of the broader industry over the same period. We expect DaVita’s constant efforts to upgrade kidney-care services with initiatives like Alliance Site Network to boost the share price in the near term.
Coming back to the news, management claims that of late there has been a rise in demand for clinical trials within a unified network for patients with early stage kidney disease. DaVita’s operating and quality systems, combined with its network of independent nephrologists, meet that need.
The company, through DCR, has opened 10 Alliance Sites in seven states. Clinical trials at these sites will emphasize on the growing pipeline of new therapies for CKD stages 1 through 4 and other conditions manifesting as a result of kidney disease. The company also plans to open an additional five Alliance Sites by the end of 2017 with further expansion planned in 2018 and beyond.
Apart from this, DaVita operates Affiliate Site Network, a similar clinical research program through DCR. This network conducts clinical research trial for end stage renal disease patients receiving hemodialysis at around 200 DaVitadialysis centers across the U.S.
As per an Allied Market Research report, the global dialysis market is estimated to reach a worth of $118.5 million by 2023, registering a CAGR of 4.5% from 2017 to 2023. This provides ample scope for DaVita to cash in on opportunities in this growing market.
Zacks Rank & Key Picks
DaVita currently carries a Zacks Rank #3 (Hold). Some better-ranked medical stocks are Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technology and Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock added roughly 21% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 96%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 17% over the last three months.
3 Top Picks to Ride the Hottest Tech Trend
Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy...
Last year, it was generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. Download Report with 3 Top Tech Stocks >>